Status:
COMPLETED
Neuropathy in Patients Monitored for Wild-type TTR Cardiac Amyloidosis (Non-mutated)
Lead Sponsor:
University Hospital, Bordeaux
Conditions:
Wild-type Amyloid Cardiopathy
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Transthyretin (TTR) amyloidosis is a rare disabling disorder that can be hereditary or sporadic. Depending on the form, various tissues are affected. While in hereditary cases, neuropathy is predomina...
Detailed Description
Transthyretin (TTR) amyloidosis belongs to a group of severe and multi-systemic diseases caused by an extracellular accumulation of fibrillar proteins arranged in beta-pleated sheets. This pathology c...
Eligibility Criteria
Inclusion
- Patients of both gender, over 18 years old, with transthyretin amyloid cardiopathy according to one of the two American Heart Association definitions of 2016
- No mutation in the TTR gene
- Patients giving their free and informed consent to participate after information about the research
- Patients affiliated to or benefiting from a social security scheme
Exclusion
- Patients with chronic neuropathy related to a known aetiology
- Patients under guardianship or curatorship
Key Trial Info
Start Date :
March 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2023
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT04828928
Start Date
March 23 2021
End Date
March 31 2023
Last Update
October 6 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Bordeaux
Bordeaux, France, 33076
2
CHU de Nantes
Nantes, France, 44093
3
CHU de Toulouse
Toulouse, France, 31059